En Es
Categories

Industry News

QIAGEN Enters into Agreement to Acquire STAT-Dx

By Labmedica International staff writers
13 Feb 2018

Image: Qiagen plans to acquire diagnostics developer STAT-Dx for up to $191 million, in a deal designed to facilitate the buyer's planned launch later this year of the QIAstat-Dx platform, based on STAT-Dx’s proprietary DiagCORE technology (Photo courtesy of STAT-Dx).QIAGEN N.V. (The Netherlands) has entered into an agreement to acquire STAT-Dx (Barcelona, Spain), a privately-held company which develops next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.

The system, which will be branded as QIAstat-Dx, enables scalable Sample to Insight processing of up to 48 molecular targets simultaneously for diagnosing syndromes, such as serious respiratory or gastrointestinal infections, as well as for use in oncology. With cost-efficient, easy-to-use assays suitable for any clinical sample type, the system can provide qualitative as well as quantitative insights into the precise cause of various syndromes in about one hour.

Based on the proprietary DiagCORE technology, the system received a first CE-IVD marking in January 2018. The system utilizes cost-efficient, single-use cartridges with built-in sample processing and all reagents on board. The cartridges are loaded with QIAGEN sample and assay technologies and a lab technician only needs to load a clinical sample into a cartridge and place it in the analyzer, requiring less than one minute of hands-on time.

The flexible modular system, which has bi-directional LIS (laboratory information system) interface capabilities, is designed to operate in a range of near-patient clinical settings, eliminating the delay of sending samples to a centralized laboratory. The cartridges are processed in a scalable, proprietary and fully integrated platform, which can be configured from one to eight modules, independently running cartridges with predefined assay protocols and managed via a touchscreen that offers simple step-by-step directions.

QIAstat-Dx is planned to be further developed with the aim of becoming the first analyzer that combines capabilities to run the highest multiplexing molecular diagnostic assays with the ability to quantitate and also process immunoassays. The first two tests, which are extensive respiratory and gastrointestinal (GI) panels, are to be launched in Europe in the second half of 2018, in the US in 2019 following regulatory clearance, and in other markets worldwide. Additional tests are under development for infectious diseases, immune response monitoring, oncology and companion diagnostics.

“QIAstat-Dx represents the next generation of innovation for multiplex syndromic testing, using powerful QIAGEN technologies and a real-time PCR technology that will allow for a much broader range of applications and drive the dissemination of molecular testing. The system is designed for significantly more cost-efficient test processing as required by the current reimbursement environment. Additional application areas for this system include companion diagnostics, quantitative analysis and immunoassay tests, offering customers a new level of flexibility and accurate diagnosis designed to support better outcomes for patients and healthcare systems,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. “We look forward to adding QIAstat-Dx to our portfolio of Sample to Insight solutions. This is further confirmation as to how we are leveraging our advantages in sample and assay technologies, our leadership in providing solutions for infectious disease testing and the global reach of our commercial teams.”

“We are excited about accelerating the commercialization of our technology to bring fast, cost-effective syndromic testing closer to care for patients and healthcare providers. At the closing of the transaction, we will build on the achievements of our fantastic team in developing a best-in-class system and leverage QIAGEN’s resources with extensive R&D and commercial reach around the world,” said Jordi Carrera, co-founder and Chief Executive Officer of STAT-Dx.



E-mail Print
FaceBook Twitter Google+ Linked in

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including complete kits for pre-defined applications in sample preparation and analysis, and individual enzymes and reagents. It also offers instruments for automating the full range of laboratory procedures, from the initial sample preparation to the final test result.
More info

More articles about QIAGEN

12 Jan 2017
Qiagen Acquires Bioinformatics Firm OmicSoft
QIAGEN N.V., a provider of sample and assay technologies, has acquired OmicSoft Corporation, which focuses on biomarker data management, visualization, and analysis.
Read More

Additional news

23 Feb 2018
AI Applications Predict Part Failures in Imaging Modalities
Machine data analytics company, Glassbeam, Inc. has built Artificial Intelligence (AI) applications powered by Machine Learning (ML) models for predicting part failures in expensive imaging modalities. The new applications delivered in real time through cloud-based dashboards and rules-based alerts are expected to change the way equipment maintenance is currently performed by in-house support staff at healthcare providers, independent service organizations (ISOs), and OEMs.
Read More
23 Feb 2018
Top Factors Driving Global POC Glucose Monitoring Devices Market
The global market for POC blood glucose monitoring devices is expected to grow at a CAGR of over 8% during the period 2018-2022, driven mainly by public and private initiatives to reduce diabetic cases. These are the latest findings of Technavio Research, a global technology research and advisory company.
Read More
21 Feb 2018
Stroke Detection Software Receives FDA Clearance
The US FDA has approved a new clinical decision support software that notifies neurologists about a potential stroke in their patients by analyzing computed tomography (CT) results. The tool named Contact has been developed by Viz.ai, a direct-to-intervention healthcare company that uses artificial intelligence (AI) and deep learning algorithms to analyze medical data and improve medical workflow.
Read More
21 Feb 2018
AI in Medical Imaging to Surge in Coming Years
The use of machine learning or artificial intelligence (AI) technology by hospitals and imaging centers is expected to surge by 2020, with its highest application to be in the area of breast imaging.
Read More
21 Feb 2018
New Deep Learning-Based Algorithm Can Assess Breast Density
Researchers from the University of Pittsburgh Medical Center have developed a new deep learning-based algorithm for breast density segmentation and estimation that correlated well with BI-RADS density assessments by radiologists and also outperformed an existing state-of-the-art algorithm.
Read More
08 Feb 2018
AI Could Learn How to Understand Radiologist Reports
Researchers at the Icahn School of Medicine at Mount Sinai have used machine learning techniques, including natural language processing algorithms, to identify clinical concepts in radiologist reports for computed tomography (CT) scans. The technology marks an important first step in the development of artificial intelligence (AI) that could interpret scans and diagnose conditions.
Read More
08 Feb 2018
AR and VR in Healthcare Market to Reach USD 4.9 Million by 2023
The augmented reality (AR) and virtual reality (VR) in the healthcare market was valued at USD 769.2 million in 2017 and is expected to grow at a CAGR of 36.6% during the forecast period to reach USD 4,997.9 million by 2023. The market growth will be driven by increasing penetration of connected devices in the healthcare sector, rising investment in healthcare AR and VR, and growing need to reduce healthcare costs. However, the lack of competence in the deployment of AR and VR solutions, and lack of expertise among medical practitioners to adopt new technologies are the major restraints for market growth.
Read More
08 Feb 2018
Elekta Collaborates with IBM Watson Health to Bring AI to Oncology
Elekta is collaborating with IBM Watson Health to offer Watson for Oncology with its cancer care solutions. Beginning in early 2018, Elekta will sell Watson for Oncology as a clinical decision support solution, paired within its digital cancer care solutions, including the MOSAIQ Oncology Information System.
Read More
08 Feb 2018
AR System Allows Surgeons to Reconnect Blood Vessels
A team of researchers at Imperial College London at St Mary’s Hospital has demonstrated the use of Microsoft HoloLens headset for performing reconstructive lower limb surgery on patients. The HoloLens is a self-contained computer headset that immerses the wearer in ‘mixed reality’, allowing them to interact with ‘holograms’ which are computer-generated objects made visible through the visor.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions